FDA Policy Analysis: First Flavored Vape Authorization and the Enforcement Discretion Guidance — Two Signals at Once

On May 5 and May 8, 2026, the FDA issued two decisions with significant consequences for the vape industry, releasing an opening and a tightening in its regulatory posture at the same time. Every Chinese vape company exporting to the United States should take note.

I. The Two Decisions at a Glance

May 5: A First for Flavored Vapes

Through the PMTA (premarket tobacco product application) pathway, the FDA authorized four closed-system pods from Glas (5% nicotine):

• Classic Menthol
• Fresh Menthol
• Gold (mango)
• Sapphire (blueberry)

Gold and Sapphire are the first non-tobacco, non-menthol flavored vape products the FDA has ever authorized — formally breaking through the flavor barrier in PMTA.

The key to approval was Device Access Restriction ("DAR") technology:

• the user must complete age and identity verification with a government-issued ID;
• the device pairs with a smartphone over Bluetooth and will not operate away from the paired phone; and
• the app performs random biometric checks to confirm the actual user is the registered adult.

Bret Koplow, acting director of the FDA's Center for Tobacco Products, called device access restriction a "potential game changer." With these authorizations, the FDA has now approved 45 vape products for market.

Reports indicated that, over the preceding weekend, President Trump had rebuked FDA Commissioner Marty Makary in a series of White House calls and meetings for not moving quickly enough to authorize flavored vape and nicotine products. Whether the May 5 authorizations are connected has been the subject of outside speculation.

May 8: Enforcement Priorities Guidance

The FDA simultaneously issued guidance on enforcement priorities for certain new tobacco products lacking premarket authorization, defining the scope of what it will not prioritize for enforcement:

• products with a PMTA accepted and pending FDA review;
• products with a supplemental PMTA (sPMTA) accepted and pending more than 180 days;

with the qualification that, for non-tobacco flavored vapes, the application must already contain the data the FDA needs to assess whether the product is appropriate for the protection of public health (APPH).

But where a product crosses the following lines, the FDA will continue to act — working with Customs (CBP) and the Department of Justice to seize and destroy at ports and borders:

• cartoon imagery;
• designs disguised as toys, phones, or game consoles;
• excessively high nicotine content;
• serious adverse events;
• lack of child-resistant packaging (violating the Child Nicotine Poisoning Prevention Act); and
• fire hazards.

II. Three Trends

1. From "flavor restriction" to dual-track regulation: technology plus compliance

What allowed Glas to break the impasse was blocking youth access at the hardware level through device-based age locking.

This means:

• the approval pathway for non-tobacco flavors is not closed; but
• the threshold has risen to demonstrating, technically, the ability to block youth access.

The FDA has begun formally accepting technological governance as a route to satisfying a public health standard — a significant evolution in its regulatory thinking.

2. Breathing room for the compliant; harder enforcement against the rest

The May 8 guidance is not a relaxation. It is the FDA optimizing limited enforcement resources — pointing the blade at the worst conduct: those who never file a PMTA at all, who counterfeit labeling, who smuggle product across the border.

Congress has appropriated $200 million for fiscal year 2026 specifically to combat illegal vape products.

In other words: filing a PMTA and cooperating with review is now the baseline for survival, and the grey zone is being compressed to its limit.

3. An accelerating compliance shakeout in the U.S. market

With 45 authorized products to date, and with many states having legislated compliant-product directories, products without a PMTA are being systematically cleared from retail. The U.S. vape market will foreseeably be dominated by a small number of compliant, innovation-driven products.

III. Three Recommendations for Chinese Vape Companies

China produces more than 90% of the world's vapes, and the United States is a core export market. In light of the FDA's direction, LawMay recommends:

First, revisit the product development roadmap and build device-level age verification into the next generation.

Glas's success is a clear signal: products with hardware age locks, Bluetooth pairing, and biometric verification will hold a marked advantage in PMTA review. Companies should:

• initiate the relevant R&D early; and
• provide complete scientific data and real-world use evidence on the actual effectiveness of device-level age verification in the PMTA submission.

That is the key pillar for breaking through the flavor barrier for non-tobacco products.

Second, audit product appearance and marketing materials thoroughly and stay clear of the FDA's stated red lines.

Cartoon imagery, designs disguised as toys, phones, or gaming devices, excessive nicotine concentration, and absent child-resistant packaging are both high-risk grounds for refusal and priority targets for border seizure and warning letters. Companies should:

• systematically review the industrial design, brand imagery, and advertising assets of products on sale and in development; and
• avoid any visual element that could be found to have potential appeal to youth.

Third, strengthen import compliance and end-to-end risk management.

Joint FDA–CBP–DOJ enforcement continues to intensify, and border seizure has become the most direct risk for exporters. Specifically:

• avoid misdeclaration, under-declaration, or false declaration in any form; and
• given the FDA's steadily rising enforcement over the past year and its explicit posture in the May 8 guidance, filing a PMTA is no longer a question of whether. Filing an initial PMTA and obtaining an acceptance letter secures a window for sales and is good value for any company intending to continue competing in the U.S. market.

For products pending PMTA review:

• retain clear evidence of acceptance;
• maintain communication with the regulatory health project manager (RHPM) where necessary; and
• seek inclusion on the FDA's forthcoming public list of products not prioritized for enforcement (by email to CTP_enforcementpriorities@fda.hhs.gov).

Conclusion

The FDA's pairing of authorization with enforcement is defining the compliance boundary of the U.S. vape market. The traditional export model — low-threshold filings, fast shipment, grey channels — is no longer sustainable.

For Chinese vape exporters, this adjustment is both a compliance challenge and an opportunity for industrial upgrading. Only by balancing scientific rigor, compliance, and market strategy can a company secure long-term room to operate in an increasingly strict U.S. regulatory environment.

References

• U.S. Food & Drug Administration, FDA Expands Market Access, Authorizes New ENDS Products (May 5, 2026)
• U.S. Food & Drug Administration, FDA Issues Guidance on Enforcement Priorities for Unauthorized ENDS and Nicotine Pouch Products (May 8, 2026)

This article addresses general legal questions only and does not constitute legal advice on any specific matter.